医学
传统PCI
血管成形术
经皮冠状动脉介入治疗
心肌梗塞
置信区间
临床终点
靶病变
荟萃分析
相对风险
内科学
随机对照试验
再狭窄
心脏病学
外科
观察研究
临床试验
冠状动脉疾病
介入心脏病学
支架
气球
经皮
系统回顾
放射科
病变
作者
Diego Mondragón,D. Garín,Stéphane Cook,Guido Knapp,M G De Togni,Serban Puricel,Pascal Meier
出处
期刊:Heart
[BMJ]
日期:2026-07-20
卷期号:: heartjnl-2026
被引量:1
标识
DOI:10.1136/heartjnl-2026-328324
摘要
BACKGROUND: Drug-coated balloon (DCB) angioplasty has emerged as a potential stent-free strategy for percutaneous coronary intervention (PCI) in de novo coronary artery disease, but robust randomised evidence on safety and efficacy compared with drug-eluting stents (DES) remains limited. METHODS: We conducted a comprehensive systematic review and meta-analysis of randomised controlled trials comparing DCB angioplasty with DES for de novo coronary lesions in adult patients reporting clinical outcomes at ≥9 months. PubMed, Embase and Cochrane CENTRAL were searched from inception to October 2025 without language restriction; trial registries and reference lists were screened manually. Studies limited to in-stent restenosis, bifurcation PCI or observational designs were excluded. Data were extracted independently by two reviewers. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random-effects models (DerSimonian-Laird method with Hartung-Knapp adjustment). Heterogeneity was assessed with I² and τ² statistics and 95% prediction intervals were reported. Risk of bias was appraised with the Cochrane Risk of Bias 2 tool. RESULTS: Seven trials encompassing 7138 patients (DCB 3570; DES 3568) were included. At 12 months, the device-oriented composite endpoint (cardiac death, target vessel myocardial infarction and target lesion revascularisation) showed no difference between strategies (RR 1.02, 95% CI 0.63 to 1.64; p=0.93; I²=52%). Secondary outcomes were comparable: cardiac death (1.26, 0.75 to 2.14), target vessel MI (0.71, 0.36 to 1.39), target lesion revascularisation (1.09, 0.52 to 2.30) and target vessel revascularisation (0.98, 0.58 to 1.65). Sensitivity analysis supported the stability of the primary findings. Trials using sirolimus coated balloons demonstrated similar results. CONCLUSIONS: DCB angioplasty shows comparable short-term safety and efficacy to modern DES for de novo coronary disease. Long-term follow-up is necessary to confirm whether avoidance of permanent implants translates into clinical benefit. PROSPERO REGISTRATION NUMBER: CRD420251175063.
科研通智能强力驱动
Strongly Powered by AbleSci AI